Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography.

O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED.

J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):356-62. Epub 2006 Nov 29.

2.

Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer's disease and dementia with Lewy bodies.

Colloby SJ, Perry EK, Pakrasi S, Pimlott SL, Wyper DJ, McKeith IG, Williams ED, O'Brien JT.

Am J Geriatr Psychiatry. 2010 Jan;18(1):86-90. doi: 10.1097/JGP.0b013e3181b972aa.

PMID:
20094022
3.

Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations.

O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED.

Neuroimage. 2008 Apr 15;40(3):1056-63. doi: 10.1016/j.neuroimage.2008.01.010. Epub 2008 Jan 19.

PMID:
18295510
4.

Alterations in nicotinic α4β2 receptor binding in vascular dementia using ¹²³I-5IA-85380 SPECT: comparison with regional cerebral blood flow.

Colloby SJ, Firbank MJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED, O'Brien JT.

Neurobiol Aging. 2011 Feb;32(2):293-301. doi: 10.1016/j.neurobiolaging.2009.02.005. Epub 2009 Mar 9.

PMID:
19269714
5.

Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors.

Saji H, Ogawa M, Ueda M, Iida Y, Magata Y, Tominaga A, Kawashima H, Kitamura Y, Nakagawa M, Kiyono Y, Mukai T.

Ann Nucl Med. 2002 May;16(3):189-200.

PMID:
12126044
6.

Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT.

Mamede M, Ishizu K, Ueda M, Mukai T, Iida Y, Fukuyama H, Saga T, Saji H.

J Nucl Med. 2004 Sep;45(9):1458-70.

7.

Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology.

Okada H, Ouchi Y, Ogawa M, Futatsubashi M, Saito Y, Yoshikawa E, Terada T, Oboshi Y, Tsukada H, Ueki T, Watanabe M, Yamashita T, Magata Y.

Brain. 2013 Oct;136(Pt 10):3004-17. doi: 10.1093/brain/awt195. Epub 2013 Aug 24.

PMID:
23975517
8.

5-[123I]Iodo-A-85380: assessment of pharmacological safety, radiation dosimetry and SPECT imaging of brain nicotinic receptors in healthy human subjects.

Ueda M, Iida Y, Mukai T, Mamede M, Ishizu K, Ogawa M, Magata Y, Konishi J, Saji H.

Ann Nucl Med. 2004 Jun;18(4):337-44.

PMID:
15359928
9.

A spatial covariance 123I-5IA-85380 SPECT study of α4β2 nicotinic receptors in Alzheimer's disease.

Colloby SJ, Field RH, Wyper DJ, O'Brien JT, Taylor JP.

Neurobiol Aging. 2016 Nov;47:83-90. doi: 10.1016/j.neurobiolaging.2016.07.017. Epub 2016 Jul 30.

10.

Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography.

Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, Luthardt J, Schildan A, Patt M, Sorger D, Seese A, Gertz HJ, Sabri O.

Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):515-25. doi: 10.1007/s00259-010-1644-5. Epub 2010 Nov 11.

PMID:
21069319
11.

Effect of linearization correction on statistical parametric mapping (SPM): a 99mTc-HMPAO brain perfusion SPECT study in mild Alzheimer's disease.

Ansar MA, Osaki Y, Kazui H, Oku N, Takasawa M, Kimura Y, Begum NN, Ikejiri Y, Takeda M, Hatazawa J.

Ann Nucl Med. 2006 Oct;20(8):511-7.

PMID:
17134017
12.

Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.

Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, Perry RH, Perry EK, Wyper D.

Neuropsychopharmacology. 2004 Jan;29(1):108-16.

13.

Noninvasive evaluation of nicotinic acetylcholine receptor availability in mouse brain using single-photon emission computed tomography with [(123)I]5IA.

Matsuura Y, Ueda M, Higaki Y, Watanabe K, Habara S, Kamino S, Saji H, Enomoto S.

Nucl Med Biol. 2016 Jun;43(6):372-8. doi: 10.1016/j.nucmedbio.2016.02.007. Epub 2016 Mar 3.

PMID:
27260778
14.

Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT.

Pakrasi S, Colloby SJ, Firbank MJ, Perry EK, Wyper DJ, Owens J, McKeith IG, Williams ED, O'Brien JT.

J Neurol. 2007 Jul;254(7):907-13. Epub 2007 Mar 14.

PMID:
17361343
15.

alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis.

Terrière E, Sharman M, Donaghey C, Herrmann L, Lonie J, Strachan M, Dougall N, Best J, Ebmeier KP, Pimlott S, Patterson J, Wyper D.

Neurochem Res. 2008 Apr;33(4):643-51. Epub 2007 Oct 25.

PMID:
17960479
17.

Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.

Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, Poewe W, Ransmayr G.

Eur J Nucl Med. 1997 Mar;24(3):320-5.

PMID:
9143472
18.

Alzheimer's disease: scintigraphic appearance of Tc-99m HMPAO brain spect.

Lee BF, Liu CK, Tai CT, Chiu NT, Liu GC, Yu HS, Pai MC.

Kaohsiung J Med Sci. 2001 Aug;17(8):394-400.

PMID:
11715838
19.
20.

Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT.

Oishi N, Hashikawa K, Yoshida H, Ishizu K, Ueda M, Kawashima H, Saji H, Fukuyama H.

J Neurol Sci. 2007 May 15;256(1-2):52-60. Epub 2007 Mar 23.

PMID:
17367812

Supplemental Content

Support Center